Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 11, Issue 12 (2022)

Assessment of respiratory toxicity following 28 days exposure of acrylamide in adult male zebrafish: Histological impairment in gills

Author(s):
Harsh R Patel, Harshad B Patel, Bhulesh V Paida, Pavan M Patel, Divya M Ramchandani, Urvesh D Patel and Chirag M Modi
Abstract:
Acrylamide is a widespread an environmental pollutant that can produce severe negative effects on fish even at very low and high concentrations. In the present study, Histopathological changes in the gills of zebrafish were evaluated following exposure of ACR (8.5 and 17 mg/L) for 28 days in adult male zebrafish. Total 18 adult male zebrafish were randomly divided into three groups. The zebrafish of control group were maintained in normal condition without any treatment (Reverse osmosis water with standard range of temperature and pH). The zebrafish of second group were maintained in R.O. water containing ACR at the strength of 8.5 mg/L. The zebrafish of third group were maintained in R.O. water containing ACR at the strength of 17 mg/L of water. In conclusion, Acrylamide exposure of second group (8.5 mg/L) shown normal architecture of gills of adult male zebrafish, However third group (17 mg/L) showed congestion (C) in primary lamellae along with fusion/clubbing (F) of secondary lamellae, epithelial hyperplasia (H) at the end of secondary lamellae and vacuolization (V) formation of secondary lamellae in gills of adult male zebrafish. In conclusion, Acrylamide exposure at 17 mg/L for 28 days produced remarkable histopathological changes in gills of adult male zebrafish.
Pages: 1005-1008  |  248 Views  102 Downloads


The Pharma Innovation Journal
How to cite this article:
Harsh R Patel, Harshad B Patel, Bhulesh V Paida, Pavan M Patel, Divya M Ramchandani, Urvesh D Patel, Chirag M Modi. Assessment of respiratory toxicity following 28 days exposure of acrylamide in adult male zebrafish: Histological impairment in gills. Pharma Innovation 2022;11(12):1005-1008.

Call for book chapter